Emulation of the SOUL Diabetes Trial in Healthcare Claims
NCT06659718
Active Not Recruiting
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
12/18/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims
NCT06659744
Active Not Recruiting
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
12/18/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
NCT05119179
Recruiting
This project uses both transcriptomic- and genomic-level data to identify mechanisms of individual responses to glucagon-like peptide-1 (GLP-1) in Mexican-Americans with prediabetes. The GLP-1 hormone is essential for glucose reduction, weight loss, cardiovascular risk reduction, and renal protection. Newly discovered mechanisms will illuminate causal links between disease genotype and phenotype, which may ultimately guide personalized therapeutic approaches for type 2 diabetes, prediabetes, obe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: UTHealth Clinical Research Unit (CRU) at UT Brownsville, Brownsville, Texas
Conditions: PreDiabetes
Register for Updates
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
NCT05786521
Active Not Recruiting
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.
Gender:
ALL
Ages:
Between 65 years and 90 years
Trial Updated:
11/21/2024
Locations: UT Health San Antonio, San Antonio, Texas
Conditions: Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity
Register for Updates
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
NCT05819138
Recruiting
This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way.... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
11/15/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +1 locations
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Prevention of Progression of Prediabetes, Obesity and CV Risk
NCT06446531
Recruiting
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Pre-Diabetes, Weight, Body, Cardiovascular Diseases
Register for Updates
A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose
NCT05689099
Completed
In this study, a known investigational medicine called 'semaglutide' will be tested in 2 drug concentrations of 0.68 milligram per milliliter (mg/mL) and 1.34 mg/mL. Both drug concentrations are tested for the treatment of type 2 diabetes. The U.S. Food and Drug Administration (FDA), has approved semaglutide in prefilled pen-injector form. Currently, the drug concentration of 1.34 mg/ml can be prescribed in some countries including U.S. The objective of the study is to compare the amount of inve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
10/13/2024
Locations: Altasciences Clinical LA, Inc., Cypress, California
Conditions: Diabetes Mellitus, Type 2, Healthy Participants
Register for Updates
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
NCT05486065
Completed
This study compares how three doses of semaglutide work in participants with type 2 diabetes (T2D) and overweight who are taking metformin. The study will look mainly at how well participant's blood sugar and participant's body weight are controlled when they are taking the study medicine at different doses. Participants will either get semaglutide \[2 milligrams (mg), 8 mg, or 16 mg\] or semaglutide placebo (a dummy medicine). Participants will take the study medicine with an injection pen call... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
10/10/2024
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +71 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
NCT04916470
Completed
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight. This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart failure symptoms. Participants will either get semaglutide or "dummy" medicine, which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Eastern Shore Rsrch Inst, LLC, Fairhope, Alabama +117 locations
Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Register for Updates
Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data
NCT05577728
Completed
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
NCT05478252
Completed
The study compares two semaglutide medicines and looks at how well they control blood sugar levels, in participants with type 2 diabetes (T2D). Participants will either get the currently available semaglutide or the semaglutide which is produced through a new manufacturing process. Participants need to take one injection of semaglutide once a week, on the same day of every week. Participants will have a total of 11 clinic visits and the study will last for about 35 weeks (approximately 8 months)... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/16/2024
Locations: Velocity Clinical Research San Diego, La Mesa, California +64 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
NCT05227196
Completed
The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood in two different tablet versions of Semaglutide. The study will consist of 3 groups and the treatment the participants will get is dependent on the group the participants will be enrolled in. The participants in group 1 will receive treatment for 22 weeks, group 2 for 21 weeks and group 3 for 20 weeks. The study will last up to 29 to 31 weeks for each participant. This includes a screenin... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/06/2024
Locations: Altasciences Clinical LA, Inc., Cypress, California +2 locations
Conditions: Healthy Volunteers, Type 2 Diabetes
Register for Updates